ChristianaCare

All visitors are required to wear masks.

For COVID-19 safety, all visitors to ChristianaCare facilities and services are required to wear masks. This includes visitors who are vaccinated. Please read our visitor guidelines before arrival.

Masks required at outpatient locations; visitors and support persons limited

All visitors at outpatient locations must be masked in alignment with the masking guidelines on our visitation policy page here. Patients at ChristianaCare’s outpatient services are advised to come to their appointments alone unless a support person is absolutely needed. If a support person is needed, such as a parent, guardian or spokesperson, we highly encourage that the support person be vaccinated. Outpatient practices are not requiring vaccination or a negative COVID test for visitors at this time.

All hospital visitors required to be vaccinated or have a negative COVID-19 test.

  • Inpatients in our Christiana, Wilmington and Union hospitals may have one visitor daily between 10 a.m. and 8 p.m. The visitor must be 16 or older.
  • Patients having outpatient surgery may have one support person accompany them. Support persons must be 16 or older.
  • All visitors and surgical support people must show proof of vaccination OR a negative COVID-19 test within the prior 72 hours.

Before visiting, click here for more details about visitation.

Visit coronavirus.delaware.gov or cecilcountyhealth.org for local vaccination and testing sites.

Helen F. Graham Cancer Center
& Research Institute

How Cancer Research Benefits You

ChristianaCare’s cancer clinical trials program actively pursues today’s most promising studies for the prevention and treatment of cancer. When you join a cancer research study, you benefit from techniques and therapeutic advances that are at the vanguard of medical science. At the same time, you are helping to improve our knowledge in ways that will help people with cancer live longer and enjoy a better quality of life.

The Helen F. Graham Cancer Center & Research Institute enrolls seven times more patients in National Cancer Institute clinical trials than the national rate. We have received several national awards for our record-breaking success in enrolling patients in clinical trials. At any given time, we have at least 700 patients enrolled in as many as 130 different clinical trials. For our patients, this success means that they have access to the best treatments and procedures available to fight their type of cancer.

Translational research: From bench to bedside

In 2009, the Helen F. Graham Cancer Center & Research Institute expanded to include wet labs and a new home for the Center for Translational Research, a partnership that includes the University of Delaware, Nemours / A.I. du Pont Hospital for Children, Rice University / BioScience Research Collaborative and the Delaware Biotechnology Institute, among others. This partnership is a powerful link that allows physicians and scientific researchers to work side-by-side, identifying needs of individual patients at the bedside, bringing those problems to the lab to explore solutions, and then returning to the bedside where those new solutions can be used to help the patient.

Translational research studies are extending the boundaries of what we know about cancer. The Helen F. Graham Cancer Center & Research Institute is collecting human tissue samples to help scientists in their laboratories learn more about the growth and development of cancer. This expanding tissue-banking effort is one of only two such non-university-based programs in the country. Increased tissue procurement enhances the resources available for translational research studies that involve the application of basic science toward potential therapies.

Helen F. Graham Cancer Center & Research Institute
4701 Ogletown-Stanton Road, Newark, DE 19713 directions
302-623-4500